Tulsa Wealth Advisors INC Purchases Shares of 5,824 IQVIA Holdings Inc. $IQV

Tulsa Wealth Advisors INC purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 5,824 shares of the medical research company’s stock, valued at approximately $1,313,000.

Several other hedge funds also recently modified their holdings of the stock. Brighton Jones LLC grew its stake in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares in the last quarter. Empowered Funds LLC boosted its holdings in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after buying an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC bought a new position in shares of IQVIA in the second quarter valued at $514,000. First Trust Advisors LP grew its stake in shares of IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after buying an additional 11,845 shares in the last quarter. Finally, NewEdge Advisors LLC increased its holdings in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after buying an additional 1,155 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of IQV stock opened at $168.14 on Friday. IQVIA Holdings Inc. has a 52 week low of $153.01 and a 52 week high of $247.04. The company has a market capitalization of $28.06 billion, a price-to-earnings ratio of 20.84, a PEG ratio of 1.44 and a beta of 1.21. The company has a 50-day simple moving average of $173.63 and a 200 day simple moving average of $191.68. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the prior year, the firm earned $2.70 EPS. The business’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA declared that its Board of Directors has approved a share repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of analysts have commented on IQV shares. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and upped their target price for the company from $174.00 to $213.00 in a report on Monday, March 9th. Weiss Ratings cut IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Royal Bank Of Canada began coverage on IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target on the stock. Finally, Evercore restated an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a research note on Wednesday, April 8th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average price target of $222.56.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.